Mice that received FRα-specific MOv19-27z T cells had readily detectable circulating human CD4+ and CD8+ T cells with significantly higher cell counts than those observed in mice treated with anti-CD19 CAR or untransduced T cells (Fig. 4c; p = 0.008 and p = 0.002, respectively), indicating that tumor antigen recognition drives the survival of the adoptively transferred FRα-specific CAR T cells in vivo. This evidence concerns the gene CD19 and neoplasm.